Professional Documents
Culture Documents
CLASSIFICATION
DRUG NAME
MECHANISM OF ACTION
THERAPEUTIC USE
Increase rate and intensity of contraction to aid and shorten the third stage of labor with
extreme caution (push out the placenta).
Reduces blood loss.
CONTRAINDICATIONS
Should not use to induce labor due to fetal harm (only use after birth).
Breastfeeding.
Hypertension, coronary artery disease, concurrent use of CYP3A4 inhibitors (grapefruit
juice).
ADVERSE EFFECTS
INTERACTIONS
NURSING CONSIDERATIONS
RESURRECTION UNIVERSITY MEDICATION CARD
ASSESSMENT
BP, pulse, character, and amount of vaginal bleeding. Watch for indications of hemorrhage
Assess uterine relaxation, observe for severe cramping.
Ergot toxicity: tinnitus, hypertension, palpitations, chest pain, nausea, vomiting, weakness,
cold, numb extremities.
PATIENT PROBLEM
Post-partum or post-labor hemorrhage, subinvolution (uterine muscle loses tone, not return
to regular size).
IMPLEMENTATION
PATIENT/FAMILY EDUCATION
Instruct patient to take medication as directed, do not skip or double up on missed doses. If
a dose is missed, exclude it, and return to regular dose schedule
Do not breast feed during treatment and for 12 hours after the last dose.
Advise patient that medication may cause menstrual-like cramp.
Do not smoke or use nicotine products.
Avoid grapefruit juice.
EVALUATION
Produce contractions that maintain uterine tone (helps deliver placenta) and prevent
postpartum hemorrhage.